Dublin "ideal location" for EMA post-Brexit, says IDA's Tommy Fanning

29 March 2017

Before UK Prime Minister Theresa May signed the decree absolute on March 29 for Britain to leave the European Union, Ireland began preparing its bid to become the new home of the European Medicines Agency (EMA), which has thus far been located in London.

Tommy Fanning of IDA Ireland, the foreign investment agency for Ireland, spoke with The Pharma Letter from Brussels - if not the heart then certainly the brain of Europe, where most of the political and regulatory machinery of the EU resides.

Joining him on a political tour of the Belgian capital was Lorraine Nolan of the Health Products Regulatory Authority (HPRA), Ireland’s regulator of medicinal products.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK